Steve Gore
Overview
Explore the profile of Steve Gore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishnamurthy A, Wang H, Rhee J, Davar D, Moy R, Ratner L, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):27.
PMID: 39841295
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models. Methods: To establish dose...
2.
Williams M, Barclay Y, Benneyworth R, Gore S, Hamilton Z, Matull R, et al.
Frontline Gastroenterol
. 2016 Oct;
7(4):323-330.
PMID: 27761233
Background: Irritable bowel syndrome (IBS) costs the National Health Service almost £12 million per annum. Despite national guidelines advising primary care management, these have failed to stem secondary care referrals...
3.
Zhao M, Rudek M, He P, Hartke C, Gore S, Carducci M, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2016 Apr;
1020:167.
PMID: 27063482
No abstract available.
4.
Heap G, So K, Weedon M, Edney N, Bewshea C, Singh A, et al.
J Crohns Colitis
. 2015 Dec;
10(2):149-58.
PMID: 26619893
Background And Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically...
5.
Lin J, Gilbert J, Rudek M, Zwiebel J, Gore S, Jiemjit A, et al.
Clin Cancer Res
. 2009 Oct;
15(19):6241-9.
PMID: 19789320
Purpose: This was a phase I trial to determine the minimal effective dose and optimal dose schedule for 5-azacytidine (5-AC) in combination with sodium phenylbutyrate in patients with refractory solid...
6.
Zhao M, Rudek M, He P, Hartke C, Gore S, Carducci M, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2004 Nov;
813(1-2):81-8.
PMID: 15556519
5-Azacytidine (5AC), a nucleoside analogue and hypomethylating agent, has anticancer properties and has been utilized in the treatment of various malignancies. 5AC is unstable and rapidly hydrolyzed to several by-products,...